Clinical Trial Update: A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer [EARLY_Phase 1]

View source ↗

Summary

A pilot Phase 1 study of the Hedgehog pathway inhibitor LDE-225 (sonidegib) for surgically resectable pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• LDE-225 (sonidegib) (sonidegib)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Resectable Pancreatic Cancer | EARLY_Phase 1 | Status: WITHDRAWN